FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, namely to immunology, and can be used for the ex-vivo determination of the cancer treatment efficiency. For this purpose, a level of activated T-lymphocytes (CD3+ CD69+) in an organism is measured after the introduction to a subject of one or more doses of an immunogenic composition. The level of the activated T-lymphocytes (CD3+ CD69+) higher than approximately 10.4% testifies to the fact that the subject is such that demonstrates successful clinical outcome for treatment; that is an increase of the survival rate.
EFFECT: application of the level of the activated T-lymphocytes (CD3+ CD69+) makes it possible to apply them as a biomarker for the monitoring, modification or correction of cancer treatment.
7 cl, 1 ex, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| BIOMARKER FOR SELECTING PATIENTS AND RESPECTIVE QUESTIONS | 2009 |
|
RU2517719C2 |
| BIOMARKER FOR PATIENT'S MONITORING | 2010 |
|
RU2542435C2 |
| BIOMARKER FOR PATIENT SELECTION AND RELATED METHODS | 2010 |
|
RU2552292C2 |
| SOLUBLE ICAM-A AS BIOMARKER FOR PREDICTION OF THERAPEUTIC RESPONSE | 2010 |
|
RU2574984C2 |
| RECOMBINANT VIRAL VACCINE | 2007 |
|
RU2453335C2 |
| CHIMERIC ANTIGEN RECEPTORS WITH MUTATED CD28 COSTIMULATION DOMAINS | 2018 |
|
RU2800922C2 |
| T-CELLS WITH TRANSDUCED ANTIGEN APPLIED AS ANTIGEN DELIVERY SYSTEMS | 2003 |
|
RU2330884C2 |
| COATED ONCOLYTIC ADENOVIRUS FOR ANTICANCER VACCINES | 2015 |
|
RU2695375C2 |
| METHOD OF PRODUCTION OF T-CELLS | 2015 |
|
RU2813668C2 |
| METHODS OF EX VIVO EXPANSION OF NATURAL KILLER CELLS AND THEIR USE | 2019 |
|
RU2814083C2 |
